CINECA IRIS Institutional Research Information System

MATRONE, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.587
AS - Asia 5.133
EU - Europa 4.312
SA - Sud America 797
AF - Africa 349
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 19.193
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.327
SG - Singapore 1.707
CN - Cina 1.400
IT - Italia 1.218
DE - Germania 968
HK - Hong Kong 737
BR - Brasile 637
SE - Svezia 564
VN - Vietnam 457
GB - Regno Unito 323
AT - Austria 238
BG - Bulgaria 221
FR - Francia 220
IN - India 181
CI - Costa d'Avorio 165
CA - Canada 155
JP - Giappone 146
RU - Federazione Russa 133
FI - Finlandia 126
TR - Turchia 122
SN - Senegal 75
BD - Bangladesh 67
AR - Argentina 57
MX - Messico 53
PL - Polonia 50
NL - Olanda 46
IQ - Iraq 41
KR - Corea 37
MA - Marocco 36
PK - Pakistan 32
ZA - Sudafrica 32
ID - Indonesia 30
ES - Italia 27
CZ - Repubblica Ceca 26
UA - Ucraina 26
UZ - Uzbekistan 22
VE - Venezuela 22
EC - Ecuador 21
EE - Estonia 20
SA - Arabia Saudita 19
CO - Colombia 17
GR - Grecia 17
AZ - Azerbaigian 16
PH - Filippine 16
CH - Svizzera 14
CL - Cile 14
IR - Iran 14
IE - Irlanda 13
LT - Lituania 13
AU - Australia 10
JM - Giamaica 10
AE - Emirati Arabi Uniti 8
CR - Costa Rica 8
EG - Egitto 8
HU - Ungheria 8
IL - Israele 8
JO - Giordania 8
PE - Perù 8
PY - Paraguay 8
TW - Taiwan 8
BE - Belgio 7
KE - Kenya 7
LB - Libano 7
MY - Malesia 7
UY - Uruguay 7
HN - Honduras 6
NP - Nepal 6
PA - Panama 6
TN - Tunisia 6
TT - Trinidad e Tobago 6
AL - Albania 5
BO - Bolivia 5
DZ - Algeria 5
GT - Guatemala 5
KZ - Kazakistan 5
MG - Madagascar 5
OM - Oman 5
PS - Palestinian Territory 5
PT - Portogallo 5
BH - Bahrain 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
TH - Thailandia 4
CY - Cipro 3
DK - Danimarca 3
ET - Etiopia 3
LV - Lettonia 3
NG - Nigeria 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
EU - Europa 2
GE - Georgia 2
LK - Sri Lanka 2
MC - Monaco 2
MK - Macedonia 2
MM - Myanmar 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
A1 - Anonimo 1
AG - Antigua e Barbuda 1
Totale 19.175
Salva come PNG Salva come JPEG
Città #
Ashburn 1.077
Singapore 968
Dallas 965
San Jose 751
Hong Kong 716
Chandler 571
Santa Clara 531
Fairfield 411
Shanghai 313
Milan 297
Beijing 259
New York 252
Houston 250
Woodbridge 223
Sofia 218
Vienna 216
Los Angeles 212
Munich 175
Seattle 175
Abidjan 165
Boardman 150
Wilmington 148
Ho Chi Minh City 134
Cambridge 133
Princeton 127
Ann Arbor 126
Pisa 126
Tokyo 121
Florence 112
Frankfurt am Main 99
Lauterbourg 98
Lawrence 95
London 89
Hanoi 83
Boulder 82
Dakar 75
Rome 74
Serra 71
Medford 66
São Paulo 66
Buffalo 65
Council Bluffs 62
Helsinki 62
Ottawa 61
Istanbul 58
Redondo Beach 55
Hefei 43
Orem 43
Dong Ket 42
Turku 42
Des Moines 39
Bremen 35
Redwood City 35
Dearborn 33
Montreal 33
San Diego 32
Denver 30
Fuzhou 30
Phoenix 30
Warsaw 30
Atlanta 29
Redmond 28
Nanjing 27
Belo Horizonte 26
Seoul 26
Düsseldorf 25
Nuremberg 24
Brooklyn 23
Tianjin 23
Washington 23
Casablanca 22
Columbus 22
Haiphong 22
Toronto 22
Amsterdam 21
Cascina 21
Chicago 21
Lucca 21
Quanzhou 21
Boston 20
Guangzhou 20
Baghdad 19
Tashkent 19
Brno 18
Ogden 18
Stockholm 18
Mumbai 17
Paris 17
Rio de Janeiro 17
San Francisco 17
Ankara 16
Chengdu 16
Johannesburg 16
Vicopisano 16
Izmir 15
Mexico City 15
Poplar 15
Bengaluru 14
Dhaka 14
Hyderabad 14
Totale 12.478
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 244
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 240
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 239
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 234
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 233
Targeted Therapy in Thyroid Cancer: State of the Art 224
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 219
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 217
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 214
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 212
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 209
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 203
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 197
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 196
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 196
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 193
Il carcinoma tiroideo: nuove prospettive terapeutiche. 191
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 189
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 189
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 188
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 188
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 187
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 183
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 182
Clinical–Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma 180
Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer 179
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 177
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 177
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 177
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 177
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 177
Risk factors for renal calcifications and determinants of hypercalciuria in patients with chronic, post-surgical hypoparathyroidism 175
Impact of energy-based devices in pediatric thyroid surgery 172
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 171
Central Neck Dissection Cannot Be Avoided In Medullary Thyroid Cancer (MTC) On The Basis Of Presurgical Serum Calcitonin (CT) 171
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 170
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 170
SAT-393 Cognitive Function Evaluation in an Italian Cohort of Patients with Post-Operative Hypoparathyroidism 167
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 163
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 163
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses 162
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 161
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 161
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 160
Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism 159
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 156
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 155
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 155
Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center 155
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 154
Prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma: 10-year impact on surgical and oncologic outcomes 152
Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series 151
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 150
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 149
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 149
Increased Risk of Renal Complications in Patients with Chronic Postsurgical Hypoparathyroidism Treated with Conventional Therapy 148
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 148
null 146
Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma 146
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 146
Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone 145
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 144
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 143
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 141
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma 139
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 138
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 137
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 137
A Patient with Advanced Medullary Thyroid Cancer and Progressive Symptomatic Distant Metastases: When to Start Systemic Therapy 136
Cabozantinib: An orphan drug for thyroid cancer 136
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 134
Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine 134
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 133
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 132
Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance 131
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 129
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 129
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 127
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 127
The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma 126
Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance 126
Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature 125
Un caso di MEN2B con anomalie scheletriche multiple 125
MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions 124
First report of benign track seeding after robot-assisted transaxillary thyroid surgery 123
Renal complications and quality of life in postsurgical hypoparathyroidism: a case–control study 121
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 119
La scintigrafia con 99mTecnezio-metossi-isobutil-isonitrile è una metodica utile per caratterizzare il rischio di malignità nei noduli tiroidei a citologia indeterminata 118
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 118
Obesity as a risk factor for thyroid cancer 117
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 117
Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma 116
Histologic parameters driving completion thyroidectomy for papillary thyroid carcinoma in a high-volume institution: A retrospective observational study 115
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 112
Hypothesizing a role of ret hyperactivation on weight control in patients with type 2A multiple endocrine neoplasia (MEN2A) 110
NF1 Gene Inactivation Acts as Tumor Driver in RET/RAS Negative Medullary Thyroid Carcinomas 110
Response to letter: "postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform131i ablation" 110
Totale 16.058
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.368
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.368
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021109 0 0 0 0 0 0 0 0 0 0 0 109
2021/20221.061 35 32 29 52 208 142 47 42 56 50 74 294
2022/20232.211 239 320 191 166 208 229 44 162 453 17 157 25
2023/20241.476 108 143 199 118 191 273 87 35 26 23 109 164
2024/20254.567 56 157 68 274 480 449 360 216 473 551 463 1.020
2025/20266.751 493 901 789 676 712 434 952 275 427 621 234 237
Totale 19.540